Pfizer to Discontinue Its Hemophilia B Gene Therapy

(MedPage Today) -- Pfizer will no longer develop and commercialize its hemophilia B gene therapy fidanacogene elaparvovec (Beqvez) across all global markets, according to multiple reports.
In a statement to Nikkei Asia, the company said that the...